La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 04, 2019 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018
October 24, 2018 16:01 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018
October 18, 2018 16:01 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
August 08, 2018 16:01 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA
August 03, 2018 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
August 01, 2018 17:39 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)
June 25, 2018 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
May 17, 2018 13:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
May 10, 2018 16:46 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
May 10, 2018 16:45 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...